New Ventures III portfolio company Royalty Pharma Announces $2.85 billion Acquisition of Royalty Rights in multiple sclerosis drug Tysabri® (natalizumab) from Perrigo Company plc

Perrigo Company plc (NYSE; TASE: PRGO) today announced it has signed a definitive agreement to divest its rights to the royalty stream from the global net sales of the multiple sclerosis drug Tysabri ® (natalizumab) to Royalty Pharma. This transaction is valued at a total consideration of up to $2.85 billion, composed of $2.2 billion in cash at closing and up to $650 million in potential milestone payments based upon future global net sales of Tysabri during 2018 and 2020. This transaction is expected to close within 30 business days, subject to certain specified closing deliverables. Read Press Release